Axsome Therapeutics, Inc.
AXSM · XNASCIK 1579428fmd_1WHC6GSEMEYP5YVJN0W8TYMBEHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 0 | 271 | 386 | 638 |
| Cost of revenue | – | – | – | – | – | – | 5 | – | – | – |
| Gross profit | – | – | – | – | – | – | (5) | – | – | – |
| Research and development | 21 | 20 | 23 | 54 | 70 | 58 | 58 | 98 | 187 | 183 |
| Selling, general and administrative | – | – | – | – | 29 | 67 | 159 | 323 | 411 | 571 |
| Total operating expenses | 28 | 27 | 33 | 67 | 99 | 125 | – | – | – | – |
| Operating income | (28) | (27) | (33) | (67) | (99) | (125) | (180) | (232) | (281) | (167) |
| Interest expense | – | – | – | – | – | – | (10) | (20) | (22) | (16) |
| Income before taxes | – | – | – | – | – | (130) | (187) | (238) | (287) | (184) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | (1) |
| Net income from continuing operations | – | – | – | – | – | (130) | (187) | (239) | (287) | (183) |
| Net income | (27) | (29) | (31) | (68) | (103) | (130) | (187) | (239) | (287) | (183) |